Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide + daratumumab + dexamethasone versus daratumumab + bortezomib + dexamethasone in relapsed or refractory multiple myeloma
NL-OMON60231Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of iberdomide, daratumumab, dexamethasone and bortezomib in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Progression-free survival and MRD-negative complete response at any time. Started Sep 2022; status: active, not recruiting.
02
Drugs
iberdomidedaratumumabdexamethasonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON60231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60231.